MGMT and neoplasm: The tumour pericyte signatures, but not the normal pericyte signatures, were strongly represented among grade III glioma patients that harboured genomic alterations prognostic of tumour progression and drug resistance, such as status on isocitrate dehydrogenase (IDH) and O6‐methylguanine‐DNA methyltransferase (MGMT).